Should Psychedelics Be Legal Medicine?
The FDA rejected MDMA therapy in 2024; Phase 2 PTSD trials showed 67% remission. Oregon is running licensed psilocybin clinics. Most promising psychiatric breakthrough in 50 years — or a hype cycle with a blinding problem? Two debaters, opposing sides — you score who makes the stronger case.
Friday, October 9, 2026 · 7:00 PM EDT
What's at stake
If the evidence holds, 50 years of Schedule I classification was a catastrophic error in medical history. If it doesn't replicate, enormous credibility has been misplaced.
The Matchup
The Positions
These compounds have the best treatment-resistant depression and PTSD data in a generation; scheduling them as Schedule I while fentanyl kills 100,000 Americans per year is a policy failure with a body count.
- Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months, a remission rate no existing treatment approaches, and psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression.
- Psilocybin mushrooms, peyote, and ayahuasca each have a documented history of safe ceremonial and therapeutic use spanning millennia; the unknown-risk framing applies to rapid pharmaceutical commercialization, not the substances themselves.
- The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm; the solution is a clear licensing pathway with rigorous therapist certification requirements, not continued prohibition of the most promising psychiatric drug class in 50 years.
Debater: To be announced
The phase-3 trials failed; the blinding problem is structurally unsolvable; and commercializing powerful psychoactive drugs before we understand them is a mistake we will spend decades cleaning up.
- The most rigorous MDMA trial, which the FDA reviewed in 2024, showed the drug did not beat placebo in one of two phase-3 studies, with a blinding problem so severe that 'double-blind' is fiction; participants always know they took the drug, making expectancy effects inseparable from pharmacological effects.
- Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts: three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions.
- The set, setting, and therapeutic relationship appear to drive most of the effect; the commercialization model of brief pill plus minimal therapy strips out what works while profiting from the brand, at the expense of patient safety.
Debater: To be announced
Join the debate
Make Your Case
Record a 60-second video on either side — or make it in writing. The strongest cases get featured before the live debate.
“Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months — a remission rate no existing treatment approaches. Psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression. For conditions that have defeated every available treatment, the evidence base is remarkable.”
“Psilocybin mushrooms, peyote, and ayahuasca each have documented histories of safe ceremonial and therapeutic use spanning millennia. The unknown-risk framing applies to rapid pharmaceutical commercialization, not to the substances themselves. Safety profiles are better understood for these compounds than for many FDA-approved medications.”
“The most rigorous MDMA trial the FDA reviewed in 2024 failed to beat placebo in one of two Phase 3 studies. The blinding problem is severe: participants almost always know they took the drug, making expectancy effects inseparable from pharmacological ones. The effect size may be mostly placebo amplified by intense therapeutic context.”
“Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts. Three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions. The vulnerability of people in altered states creates abuse risks that are not hypothetical.”
How It Works
The Format
Standard SuperDebate: two people, cross-examination, moderated from start to finish
Opening Argument
PRO · opening case
Cross-Examination
CON questions PRO
Opening Argument
CON · opening case
Cross-Examination
PRO questions CON
Rebuttal
PRO
Rebuttal
CON
Closing Statement
PRO · final case
Closing Statement
CON · final case
Audience Vote
You pick the winner
~28 minutes of debate · audience vote follows closing statements
Don't Miss It
Stay in the Loop
The debate drops when the two sides are confirmed. Get the email the moment it goes live.
Premieres
Friday, October 9, 2026 · 7:00 PM EDT
Get Involved
Open debate runs on the people who show up. Tell us how you want to be part of it.
More Debates
Structured debates on the ideas that matter most. You score who makes the stronger case.
Jordan vs. LeBron: The GOAT SuperDebate
Watch the full recorded Jordan vs. LeBron GOAT basketball debate, argued by championship debaters, then score both debaters live.
DEI: More Harm Than Good?
DEI stands for Diversity, Equity, and Inclusion. Wilfred Reilly and Armand Domalewski debate whether DEI programs move institutions toward equality, or create a new paradigm for inequality.
UBI Debate: Should America Have a Universal Basic Income?
Scott Santens (PRO) vs Malcolm Collins (CON) debate the resolution: "An unconditional basic income would be net beneficial for American citizens." — July 10, 2026, 2 PM CT.
Messi vs Ronaldo: Who Is the Soccer GOAT?
Two debaters. Assigned sides. Cross-examination. One argues the case for Messi, the other for Ronaldo — in a structured debate format with opening arguments and rebuttals.